The definitive agreement confirms the reverse merger terms. MTNB shareholders should evaluate the implied valuation of $24.7 million and the potential upside from Azurity milestones and royalties. Monitor the special stockholder meeting and PIPE financing completion as key catalysts. The stock may remain volatile until closing.
Price Chart
Executive Summary
Matinas BioPharma (MTNB) has filed a definitive business combination agreement with GH Power Inc., a clean-energy company, in a reverse merger that will result in a change of control. MTNB shareholders will receive 0.1 Pubco common shares per share, and Matinas will sell its lipid nanocrystal platform and MAT2203 product candidate to Azurity Pharmaceuticals for $4 million cash plus milestone payments and royalties. The transactions are interconditional and subject to shareholder and regulatory approvals, with an outside date of December 31, 2026.
Key Financial Metrics
Key Facts
- Matinas shareholders receive 0.1 Pubco common share per MTNB share in a reverse merger with clean-energy company GH Power.
- GH Power is valued at $250 million; Matinas' valuation set at approximately $24.7 million.
- Sale of Matinas' lipid nanocrystal platform and MAT2203 to Azurity Pharmaceuticals for $4 million cash upfront plus up to $17.5 million in milestone payments and tiered royalties on net sales.
- Minimum PIPE financing of $15 million is required to close the deal.
- The combined entity will be a clean-energy company, representing a complete business transformation for MTNB.
- Termination fee of $1 million payable by Matinas to GH Power in certain scenarios.
Financial Impact
Matinas valued at ~$24.7 million vs. current market cap of $5 million; asset sale provides $4 million upfront plus contingent milestones/royalties. Shareholders receive 0.1 Pubco share per MTNB share, implying significant dilution relative to current ownership.
Risk Factors
- Transaction may not close if shareholders vote down or PIPE financing fails.
- Matinas shareholders face severe dilution and loss of control; the combined entity will be a clean-energy company, not biotech.
- Azurity sale milestone payments are contingent on successful development and commercialization of MAT2203.
- Regulatory and court approvals required; outside date risk (December 31, 2026).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-032939 |
| Exhibit: ex2-2.htm | 0001493152-26-032939 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $2.53 $1.66 | ▼ −34.39% | ▼ −34.36% | $1.83 (−27.67%) |
Sep 16, 2026 5w ago | 8-K | $0.1630 $0.1613 | ▼ −1.02% | ▼ −2.23% | $1.83 (+1022.70%) |
Sep 4, 2026 7w ago | 8-K | $0.1820 $3.01 | ▼ −1553.85% | ▼ −1552.13% | $1.83 (−905.49%) |
Aug 25, 2026 9w ago | 425 | $0.1973 $0.1750 | ▲ +11.30% | ▲ +12.28% | $1.83 (−827.52%) |
Jul 30, 2026 12w ago | 425 | $0.3174 $0.2000 | ▲ +36.99% | ▲ +40.95% | $1.83 (−476.56%) |
Jul 24, 2026 13w ago | 8-K | $0.3320 $0.1965 | ▲ +40.81% | ▲ +44.11% | $1.83 (−451.20%) |
Jul 13, 2026 15w ago | 425 | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.83 (−281.25%) |
Jul 13, 2026 15w ago | 8-K | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.83 (−281.25%) |
Jun 26, 2026 17w ago | 8-K | $0.6640 $0.2414 | ▲ +63.64% | ▲ +63.37% | $1.83 (−175.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers